April 1, 2022

Data presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium highlight the inhibitors’ use in combination regimens, other settings, and next-generation agents.

Several notable trials in colorectal cancer suggest a shift in treatment management, especially in the length of treatment with immunotherapies.

Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.